Liquidia Co. (NASDAQ:LQDA) Receives Average Recommendation of “Buy” from Brokerages

Liquidia Co. (NASDAQ:LQDA) has earned a consensus recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $25.38.

Several equities research analysts recently weighed in on the company. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Lifesci Capital started coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective for the company. Wells Fargo & Company started coverage on shares of Liquidia in a report on Friday. They issued an “overweight” rating and a $20.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Liquidia in a report on Thursday, November 14th.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $11.44 on Tuesday. The stock has a market capitalization of $968.28 million, a P/E ratio of -7.02 and a beta of 0.22. The business has a 50-day moving average of $10.92 and a two-hundred day moving average of $11.12. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.99.

Insiders Place Their Bets

In related news, CFO Michael Kaseta sold 3,892 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the completion of the transaction, the chief financial officer now directly owns 311,076 shares in the company, valued at approximately $3,456,054.36. This represents a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Russell Schundler sold 2,576 shares of Liquidia stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $28,619.36. Following the sale, the general counsel now owns 486,048 shares in the company, valued at $5,399,993.28. This represents a 0.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,007 shares of company stock worth $245,780 in the last ninety days. Insiders own 30.10% of the company’s stock.

Hedge Funds Weigh In On Liquidia

Hedge funds have recently made changes to their positions in the business. Whitefort Capital Management LP increased its stake in Liquidia by 119.8% in the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after acquiring an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after purchasing an additional 230,820 shares during the period. Anson Funds Management LP bought a new stake in shares of Liquidia in the 3rd quarter valued at approximately $1,764,000. Sapient Capital LLC bought a new position in shares of Liquidia during the 3rd quarter worth approximately $1,336,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Liquidia by 735.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock worth $1,402,000 after buying an additional 123,402 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).